Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea
Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion while liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.
Authors
- Martin L. Kårhus (ORCID: https://orcid.org/0000-0002-3842-1287)
- Julie Lyng Forman (ORCID: https://orcid.org/0000-0001-7368-0869)
- Łukasz Krych (ORCID: https://orcid.org/0000-0003-3224-1346)
- David P. Sonne (ORCID: https://orcid.org/0000-0002-4898-2256)
- Lars Ove Dragsted (ORCID: https://orcid.org/0000-0003-0609-6317)
- Filip K. Knop (ORCID: https://orcid.org/0000-0002-2495-5034)
- Dennis Sandris Nielsen (ORCID: https://orcid.org/0000-0001-8121-1114)
- Anne‐Marie Ellegaard (ORCID: https://orcid.org/0000-0002-4389-3908)
- Svend Høime Hansen (ORCID: https://orcid.org/0000-0003-4823-1054)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Novo Nordisk (Denmark) (DK)
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.14309/ctg.0000000000000772
- Citations
- 5
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Novo Nordisk
- Novo Nordisk Fonden